Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis

Research output: Contribution to journalReview articlepeer-review

Standard

Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting : a Bayesian network meta-analysis. / Alhifany, Abdullah A.; Mcbride, Ali; Almutairi, Abdulaali R.; Cheema, Ejaz; Shahbar, Alaa; Alatawi, Yasser; Alharbi, Adnan S.; Babiker, Hani; Macdonald, Karen; Aapro, Matti; Abraham, Ivo.

In: Supportive Care in Cancer, Vol. 28, 10.12.2019, p. 1031–1039.

Research output: Contribution to journalReview articlepeer-review

Harvard

APA

Vancouver

Author

Alhifany, Abdullah A. ; Mcbride, Ali ; Almutairi, Abdulaali R. ; Cheema, Ejaz ; Shahbar, Alaa ; Alatawi, Yasser ; Alharbi, Adnan S. ; Babiker, Hani ; Macdonald, Karen ; Aapro, Matti ; Abraham, Ivo. / Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting : a Bayesian network meta-analysis. In: Supportive Care in Cancer. 2019 ; Vol. 28. pp. 1031–1039.

Bibtex

@article{c52858398aef415da4cc051d16eb1123,
title = "Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis",
abstract = "Background: Olanzapine, neurokinin-1-receptor-antagonists (NK-1-RA), and thalidomide added to palonosetron + dexamethasone (PALO-DEX) have been evaluated in separate studies as prophylaxis for chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). We conducted a Bayesian network meta-analysis to compare the prophylactic efficacy of these agents in combination with PALO-DEX.Methods: PubMed, Medline/Ovid, Embase, and Clinicaltrials.gov were searched from inception through 22 Mar 2018. Study quality was assessed using the Cochrane methodology. A Bayesian network meta-analysis using random-effects models was used to asses complete response (CR) and rate of no nausea (RNN) in acute, delayed, and overall phases and were expressed as odds ratios (OR) and 95% credible interval (95% CrI). Ranking probabilities of treatments were calculated using the surface under the cumulative ranking curve (SUCRA) to identify the probability of a given treatment as the best option against the worst option.Results: Nine RCTs involving two thousand nine hundred fifty-nine patients were included. The olanzapine-based regimen showed greater CR in the acute, delayed, and overall-phases versus the PALO-DEX regimen (OR = 3.97, 95% CrI = 1.02–19.13; OR = 5.62, 95% CrI = 1.66–28.58; OR = 4.79, 95% CrI = 1.40–24.02, respectively). Additionally, it showed greater RNN than the NK-1-RA-based and the PALO-DEX regimens in the delayed phase only (OR = 2.90, 95% CrI = 1.34–5.15; OR = 4.53, 95% CrI = 1.89–10.55, respectively). Olanzapine-, NK-1-RA-, and thalidomide-based regimens did not differ in CR in the three phases. SUCRA probabilities ranked the olanzapine-based regimen as the best option in terms of CR and RNN, while ranking the NK-1-RA-based regimens as the second best option in terms of CR throughout the three phases.Conclusion: Based on the data included in the analyses, there is insufficient evidence to support adding thalidomide or NK-1-RA to PALO-DEX in preventing CINV induced by HEC. However, adding olanzapine to PALO-DEX achieves better CR and RNN. Olanzapine side-effects and the absence of direct comparisons explain why some guidelines are cautious in suggesting the use of olanzapine.",
keywords = "Olanzapine, Neurokinin-1 receptor antagonists, Thalidomide, Palonosetron, Dexamethasone, Chemotherapy-induced nausea and vomiting, Highly emetic chemotherapy",
author = "Alhifany, {Abdullah A.} and Ali Mcbride and Almutairi, {Abdulaali R.} and Ejaz Cheema and Alaa Shahbar and Yasser Alatawi and Alharbi, {Adnan S.} and Hani Babiker and Karen Macdonald and Matti Aapro and Ivo Abraham",
year = "2019",
month = dec,
day = "10",
doi = "10.1007/s00520-019-05210-4",
language = "English",
volume = "28",
pages = "1031–1039",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer",

}

RIS

TY - JOUR

T1 - Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting

T2 - a Bayesian network meta-analysis

AU - Alhifany, Abdullah A.

AU - Mcbride, Ali

AU - Almutairi, Abdulaali R.

AU - Cheema, Ejaz

AU - Shahbar, Alaa

AU - Alatawi, Yasser

AU - Alharbi, Adnan S.

AU - Babiker, Hani

AU - Macdonald, Karen

AU - Aapro, Matti

AU - Abraham, Ivo

PY - 2019/12/10

Y1 - 2019/12/10

N2 - Background: Olanzapine, neurokinin-1-receptor-antagonists (NK-1-RA), and thalidomide added to palonosetron + dexamethasone (PALO-DEX) have been evaluated in separate studies as prophylaxis for chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). We conducted a Bayesian network meta-analysis to compare the prophylactic efficacy of these agents in combination with PALO-DEX.Methods: PubMed, Medline/Ovid, Embase, and Clinicaltrials.gov were searched from inception through 22 Mar 2018. Study quality was assessed using the Cochrane methodology. A Bayesian network meta-analysis using random-effects models was used to asses complete response (CR) and rate of no nausea (RNN) in acute, delayed, and overall phases and were expressed as odds ratios (OR) and 95% credible interval (95% CrI). Ranking probabilities of treatments were calculated using the surface under the cumulative ranking curve (SUCRA) to identify the probability of a given treatment as the best option against the worst option.Results: Nine RCTs involving two thousand nine hundred fifty-nine patients were included. The olanzapine-based regimen showed greater CR in the acute, delayed, and overall-phases versus the PALO-DEX regimen (OR = 3.97, 95% CrI = 1.02–19.13; OR = 5.62, 95% CrI = 1.66–28.58; OR = 4.79, 95% CrI = 1.40–24.02, respectively). Additionally, it showed greater RNN than the NK-1-RA-based and the PALO-DEX regimens in the delayed phase only (OR = 2.90, 95% CrI = 1.34–5.15; OR = 4.53, 95% CrI = 1.89–10.55, respectively). Olanzapine-, NK-1-RA-, and thalidomide-based regimens did not differ in CR in the three phases. SUCRA probabilities ranked the olanzapine-based regimen as the best option in terms of CR and RNN, while ranking the NK-1-RA-based regimens as the second best option in terms of CR throughout the three phases.Conclusion: Based on the data included in the analyses, there is insufficient evidence to support adding thalidomide or NK-1-RA to PALO-DEX in preventing CINV induced by HEC. However, adding olanzapine to PALO-DEX achieves better CR and RNN. Olanzapine side-effects and the absence of direct comparisons explain why some guidelines are cautious in suggesting the use of olanzapine.

AB - Background: Olanzapine, neurokinin-1-receptor-antagonists (NK-1-RA), and thalidomide added to palonosetron + dexamethasone (PALO-DEX) have been evaluated in separate studies as prophylaxis for chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). We conducted a Bayesian network meta-analysis to compare the prophylactic efficacy of these agents in combination with PALO-DEX.Methods: PubMed, Medline/Ovid, Embase, and Clinicaltrials.gov were searched from inception through 22 Mar 2018. Study quality was assessed using the Cochrane methodology. A Bayesian network meta-analysis using random-effects models was used to asses complete response (CR) and rate of no nausea (RNN) in acute, delayed, and overall phases and were expressed as odds ratios (OR) and 95% credible interval (95% CrI). Ranking probabilities of treatments were calculated using the surface under the cumulative ranking curve (SUCRA) to identify the probability of a given treatment as the best option against the worst option.Results: Nine RCTs involving two thousand nine hundred fifty-nine patients were included. The olanzapine-based regimen showed greater CR in the acute, delayed, and overall-phases versus the PALO-DEX regimen (OR = 3.97, 95% CrI = 1.02–19.13; OR = 5.62, 95% CrI = 1.66–28.58; OR = 4.79, 95% CrI = 1.40–24.02, respectively). Additionally, it showed greater RNN than the NK-1-RA-based and the PALO-DEX regimens in the delayed phase only (OR = 2.90, 95% CrI = 1.34–5.15; OR = 4.53, 95% CrI = 1.89–10.55, respectively). Olanzapine-, NK-1-RA-, and thalidomide-based regimens did not differ in CR in the three phases. SUCRA probabilities ranked the olanzapine-based regimen as the best option in terms of CR and RNN, while ranking the NK-1-RA-based regimens as the second best option in terms of CR throughout the three phases.Conclusion: Based on the data included in the analyses, there is insufficient evidence to support adding thalidomide or NK-1-RA to PALO-DEX in preventing CINV induced by HEC. However, adding olanzapine to PALO-DEX achieves better CR and RNN. Olanzapine side-effects and the absence of direct comparisons explain why some guidelines are cautious in suggesting the use of olanzapine.

KW - Olanzapine

KW - Neurokinin-1 receptor antagonists

KW - Thalidomide

KW - Palonosetron

KW - Dexamethasone

KW - Chemotherapy-induced nausea and vomiting

KW - Highly emetic chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=85076738579&partnerID=8YFLogxK

U2 - 10.1007/s00520-019-05210-4

DO - 10.1007/s00520-019-05210-4

M3 - Review article

VL - 28

SP - 1031

EP - 1039

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

ER -